CO6351719A2 - Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas - Google Patents
Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicasInfo
- Publication number
- CO6351719A2 CO6351719A2 CO11017742A CO11017742A CO6351719A2 CO 6351719 A2 CO6351719 A2 CO 6351719A2 CO 11017742 A CO11017742 A CO 11017742A CO 11017742 A CO11017742 A CO 11017742A CO 6351719 A2 CO6351719 A2 CO 6351719A2
- Authority
- CO
- Colombia
- Prior art keywords
- formula
- group
- alkyl
- lower alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de La fórmula I, un lípido y un tensoactivo; en donde el compuesto de la fórmula I tiene la siguiente fórmula estructuralEn donde (a) R1 representa un grupo dala fórmulay R2 representa hidrógeno o alquilo inferior, o R1 y R2 juntos representan un grupo de la fórmulapor lo que en las fórmulas lIa a lIi, R7 y R8 representan independientemente, hidrógeno, halógeno, trifluorometilo, hidroxi, nitro, alquilo inferior, alcoxi inferior, o -C(=O)-R15, en donde R15 representa H, hidroxilo, alquilo inferior, alcoxi (de manera que R15 junto con el grupo carbonilo es un éster), o amino (de manera que R15 junto con el grupo carbonilo es carbamoilo);R9 representa hidrógeno, halógeno, hidroxi, alquilo inferior o alcoxi inferior,X representa oxígeno, azufre, imino, alquilimino inferior o un radical de a fórmula ----(CH2)r----,p es 1, 2 ó 3,r es 1, 2 ó 3,s es 3, 4 ó 5,t es 2, 3 ó 4, y v es 3, 4, 5 ó 6; - 2 -R3 y R5 representan, independientemente, hidrógeno o alquilo inferior, y R4 representa alquilo de C1-6 o cicloalquilo de C3-8 alquilo de (C1-6); y R6 representa un grupo de la fórmulaen donde R11 representa hidrógeno, alquilo de (C1-6), opcionalmente un alquilo sustituto con a-hdiroxi; alquenilo, cicloalquilo, cicloalquilalquilo, fenilo, fenalquilo o tienilo, R12, R13 y R14 representa, independientemente, hidrógeno o alquilo inferior, yrepresenta un radical de cicloalquilideno de C5-8 opcionalmente conteniendo una doble unión; o(b) R1 representa un grupo de la fórmula lla a llg como se define bajo (a),R2 representa hidrógeno o alquilo inferior,R3 y R4 juntos forman un grupo ----(CH2)u----, en donde u es un número entero de 1 a 8, yR5 y R6 tienen los significados dados bajo (a).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8311508P | 2008-07-23 | 2008-07-23 | |
US10211108P | 2008-10-02 | 2008-10-02 | |
US15018709P | 2009-02-05 | 2009-02-05 | |
US16812209P | 2009-04-09 | 2009-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6351719A2 true CO6351719A2 (es) | 2011-12-20 |
Family
ID=41358304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11017742A CO6351719A2 (es) | 2008-07-23 | 2011-02-15 | Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas |
Country Status (15)
Country | Link |
---|---|
US (2) | US20100086504A1 (es) |
EP (1) | EP2317993A2 (es) |
JP (1) | JP2011529038A (es) |
KR (1) | KR20110039357A (es) |
CN (1) | CN102159202A (es) |
AU (1) | AU2009275230A1 (es) |
CA (1) | CA2731455A1 (es) |
CL (1) | CL2011000135A1 (es) |
CO (1) | CO6351719A2 (es) |
EC (1) | ECSP11010818A (es) |
IL (1) | IL210813A0 (es) |
MX (1) | MX2011000932A (es) |
NI (1) | NI201100025A (es) |
PE (1) | PE20110642A1 (es) |
WO (1) | WO2010010470A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2676975A1 (en) * | 2007-02-05 | 2008-08-14 | Biophile Corporation, Ltd. | Increased effectiveness of allylamine drug compounds |
CA2751412A1 (en) * | 2009-02-05 | 2010-08-12 | Targeted Delivery Technologies Limited | Methods of reducing the proliferation and viability of microbial agents |
FR2954163B1 (fr) * | 2009-12-18 | 2012-03-16 | Galderma Pharma Sa | Utilisation d'un tensioactif cationique, avantageu-sement amphotere, pour la preparation d'une composition antifongique applicable sur l'ongle |
EP2544659A2 (en) | 2009-12-23 | 2013-01-16 | Nuvo Research Inc. | Highly permeating terbinafine formulation for treating onychomycosis |
EP2672962B1 (en) * | 2011-02-11 | 2015-03-25 | Moberg Pharma AB | Novel antifungal composition |
DE112012001386T5 (de) * | 2011-03-21 | 2013-12-19 | Gregor Cevc | Optimierte Präparate von sehr anpassungsfähigen Aggregaten |
WO2013057208A1 (en) | 2011-10-18 | 2013-04-25 | Targeted Delivery Technologies Limited | Compositions and methods for reducing the proliferation and viability of microbial agents |
US8697753B1 (en) * | 2013-02-07 | 2014-04-15 | Polichem Sa | Method of treating onychomycosis |
WO2015138926A1 (en) | 2014-03-14 | 2015-09-17 | Gojo Industries, Inc. | Hand sanitizers with improved aesthetics and skin-conditioning to encourage compliance with hand hygiene guidelines |
AT516544B1 (de) | 2014-12-02 | 2017-05-15 | Universität Innsbruck | Stoffgemisch und Zubereitung |
CN105193726B (zh) * | 2015-11-08 | 2018-01-26 | 长沙佰顺生物科技有限公司 | 一种治疗灰指甲的药物组合物 |
KR101952715B1 (ko) * | 2017-09-27 | 2019-02-27 | 경희대학교 산학협력단 | 천연 화합물을 포함하는 칸디다증 개선용 항진균 조성물 |
RU2698454C1 (ru) * | 2018-11-12 | 2019-08-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) | Способ лечения онихомикозов стоп |
KR102072946B1 (ko) | 2019-08-06 | 2020-02-03 | 주식회사 씨엔엘바이오텍 | 조갑진균증 예방 또는 치료용 조성물 |
JP2022552252A (ja) * | 2019-10-08 | 2022-12-15 | ハルクス,インコーポレイテッド | 爪真菌症治療用組成物及び方法 |
AT524378A1 (de) | 2020-11-06 | 2022-05-15 | Univ Innsbruck | Zubereitung |
KR20230116911A (ko) * | 2020-12-08 | 2023-08-04 | 모베르그 파르마 아베 | 알릴아민 항진균 조성물을 사용한 조갑진균증의 치료 요법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19375084I2 (de) * | 1979-08-22 | 2000-11-16 | Novartis Ag | Propenylamine Verfahren zu ihrer Herstellung sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung als Arzneimittel |
US6005001A (en) * | 1991-05-20 | 1999-12-21 | Novartis Ag (Formerly Sandoz Ag) | Pharmaceutical composition |
GB9111611D0 (en) * | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
ATE267613T1 (de) * | 1998-03-05 | 2004-06-15 | Phares Pharm Res Nv | Arzneimittel und deren verwendung |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
GB0108082D0 (en) * | 2001-03-30 | 2001-05-23 | Novartis Consumer Health Sa | Topical composition |
US6846837B2 (en) * | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
US20040105881A1 (en) | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
RS20060479A (en) * | 2004-03-18 | 2008-11-28 | Panacea Biotec Ltd., | Novel compositions for topical delivery |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
WO2006103638A2 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Topical pharmaceutical compositions of terbinafine and processes for their preparation |
US20070077283A1 (en) * | 2005-09-30 | 2007-04-05 | Nastech Pharmaceutical Company Inc. | Method of enhancing transmucosal delivery of therapeutic compounds |
JP5467722B2 (ja) * | 2007-01-16 | 2014-04-09 | ロート製薬株式会社 | 皮膚外用乳化製剤 |
CA2676975A1 (en) * | 2007-02-05 | 2008-08-14 | Biophile Corporation, Ltd. | Increased effectiveness of allylamine drug compounds |
-
2009
- 2009-07-23 JP JP2011519254A patent/JP2011529038A/ja active Pending
- 2009-07-23 EP EP09786211A patent/EP2317993A2/en not_active Withdrawn
- 2009-07-23 WO PCT/IB2009/006742 patent/WO2010010470A2/en active Application Filing
- 2009-07-23 MX MX2011000932A patent/MX2011000932A/es not_active Application Discontinuation
- 2009-07-23 US US12/508,537 patent/US20100086504A1/en not_active Abandoned
- 2009-07-23 AU AU2009275230A patent/AU2009275230A1/en not_active Abandoned
- 2009-07-23 CN CN2009801337541A patent/CN102159202A/zh active Pending
- 2009-07-23 KR KR1020117004207A patent/KR20110039357A/ko not_active Application Discontinuation
- 2009-07-23 PE PE2011000073A patent/PE20110642A1/es not_active Application Discontinuation
- 2009-07-23 CA CA2731455A patent/CA2731455A1/en not_active Abandoned
-
2010
- 2010-01-19 US US12/689,470 patent/US7820720B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 CL CL2011000135A patent/CL2011000135A1/es unknown
- 2011-01-21 NI NI201100025A patent/NI201100025A/es unknown
- 2011-01-23 IL IL210813A patent/IL210813A0/en unknown
- 2011-02-10 EC EC2011010818A patent/ECSP11010818A/es unknown
- 2011-02-15 CO CO11017742A patent/CO6351719A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN102159202A (zh) | 2011-08-17 |
MX2011000932A (es) | 2011-05-19 |
JP2011529038A (ja) | 2011-12-01 |
KR20110039357A (ko) | 2011-04-15 |
CA2731455A1 (en) | 2010-01-28 |
CL2011000135A1 (es) | 2011-09-23 |
WO2010010470A2 (en) | 2010-01-28 |
NI201100025A (es) | 2011-11-02 |
US7820720B2 (en) | 2010-10-26 |
US20100086504A1 (en) | 2010-04-08 |
EP2317993A2 (en) | 2011-05-11 |
IL210813A0 (en) | 2011-04-28 |
US20100104633A1 (en) | 2010-04-29 |
PE20110642A1 (es) | 2011-08-31 |
WO2010010470A3 (en) | 2010-03-18 |
AU2009275230A1 (en) | 2010-01-28 |
ECSP11010818A (es) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6351719A2 (es) | Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas | |
EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
AR077701A1 (es) | Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos | |
EA201001554A1 (ru) | Ингибиторы модуляторов воспаления: производные олеанолевой кислоты, гомологированные с-17 | |
EA201500653A1 (ru) | Композиции, содержащие триазольное соединение | |
EA201001555A1 (ru) | Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17 | |
EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
AR074855A1 (es) | Derivados aminoester de alcaloides y composicion medicinal de los mismos utilizadas en el tratamiento de enfermedades mediadas por el antagonismo de los receptores muscarinicos. | |
AR076360A1 (es) | Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer | |
PE20150400A1 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
EA201290128A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
EA201490287A1 (ru) | Новые замещенные производные индола в качестве модуляторов гамма-секретазы | |
MD4425C1 (ro) | Alcoxipirazoli în calitate de activatori ai guanilat-ciclazei solubile | |
AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
AR047516A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos | |
PE20120374A1 (es) | Fenilureas y fenilamidas como ligandos del receptor de vanilloides | |
EA201491079A1 (ru) | Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2 | |
AR082103A1 (es) | Derivados de dioxido de 1,3-propano sustituidos de manera espirociclica, composiciones farmaceuticas que los contienen y su uso como agentes antidiabeticos | |
EA201071019A1 (ru) | Кристаллические формы производных фениламинопиримидина | |
CO6351789A2 (es) | Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica | |
AR086773A1 (es) | Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo | |
AR067975A1 (es) | Derivados de la n-bencil, n-arilcarbonilpiperazina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |